Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores

被引:2
|
作者
Wollenberg, Andreas [1 ,2 ]
Simon, Dagmar [3 ]
Kulthanan, Kanokvalai [4 ]
Figueras-Nart, Ignasi [5 ]
Misery, Laurent [6 ,7 ]
Tangsirisap, Nithi [8 ]
Spina, Lara [8 ]
Lu, Na [9 ]
Grond, Sussanne [8 ]
Eyerich, Kilian [10 ,11 ]
机构
[1] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergy, Munich, Germany
[2] Augsburg Univ Hosp, Dept Dermatol & Allergy, Augsburg, Germany
[3] Univ Bern, Dept Dermatol, Bern Univ Hosp, Inselspital, CH-3010 Bern, Switzerland
[4] Mahidol Univ, Fac Med, Dept Dermatol, Allergy & Immunol Unit,Siriraj Hosp, Bangkok, Thailand
[5] Univ Barcelona, Hosp Univ Bellvitge, Dept Dermatol, Barcelona, Spain
[6] Univ Hosp Brest, Dept Dermatol Venereol & Allergol, Brest, France
[7] Univ Hosp Brest, French Expert Ctr Pruritus, Brest, France
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Precis Stat Consulting, Woodbury, MN USA
[10] Univ Freiburg, Med Ctr, Dept Dermatol & Venerol, Freiburg, Germany
[11] Univ Freiburg, Med Ctr, Dept Dermatol & Venereol, Hauptstr 7, D-79104 Freiburg, Germany
关键词
MANAGEMENT; DIAGNOSIS; ITCH;
D O I
10.1111/jdv.19669
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Baricitinib treatment in adults with moderate-to-severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI) total score, whether administered as monotherapy or in combination with topical corticosteroids (TCS). As EASI clinical signs differ in time course and associated antecedents, the effects of baricitinib on each individual clinical sign are of interest.Objectives: In this post hoc analysis, we aimed to investigate the effects of baricitinib on individual EASI subscores, namely excoriation, oedema/papulation, erythema and lichenification, in both monotherapy and TCS combination therapy trials.Methods: We analysed the percent change from baseline in individual EASI subscores from three phase-III, double-blind, 16-week trials of baricitinib in monotherapy (BREEZE-AD1/BREEZE-AD2) and TCS combination therapy (BREEZE-AD7) cohorts via mixed model repeated measures (MMRM).Results: Baricitinib 4 mg showed rapid and sustained improvements in all four clinical signs in both cohorts. Significant effects emerged at week 1 for excoriation, oedema/papulation and erythema scores in monotherapy (p < 0.001) and TCS combination therapy (p < 0.001, p < 0.01, p < 0.001), plateaued at week 4, and remained significant versus placebo through week 16. The effect on lichenification scores also emerged early, at week 1 in monotherapy (p < 0.05) and week 2 in combination therapy (p < 0.001), with scores continuously improving without a clear plateau. Effect magnitude was highest in excoriation scores, exhibiting near-maximal reduction in week 1 of monotherapy and remaining highest across all timepoints in combination therapy.Conclusions: Rapid and sustained improvements were observed across clinical signs of inflammation and particularly on excoriation following baricitinib treatment. Our findings suggest that selective inhibition of janus kinases 1 and 2 leads to rapid and sustained control of skin inflammation, and that rapid reductions in itch translate into early disruption of the itch-scratch cycle.
引用
收藏
页码:695 / 702
页数:8
相关论文
共 40 条
  • [21] Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score 24 or 24
    Offidani, Annamaria
    Stingeni, Luca
    Neri, Iria
    Cipriani, Filippo
    Chen, Zhen
    Rossi, Ana B.
    Lu, Yufang
    Moretti, Devis
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2022, 157 (01) : 39 - 46
  • [22] Texting atopic dermatitis patients to optimize learning and eczema area and severity index scores: A pilot randomized control trial
    Singer, Hannah M.
    Levin, Laura E.
    Morel, Kimberly D.
    Garzon, Maria C.
    Stockwell, Melissa S.
    Lauren, Christine T.
    PEDIATRIC DERMATOLOGY, 2018, 35 (04) : 453 - 457
  • [23] The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use
    Jacobson, M. E.
    Morimoto, R. Y.
    Leshem, Y. A.
    Howells, L.
    Williams, H. C.
    Grinich, E.
    Gerbens, L. A. A.
    Spuls, P. I.
    Schmitt, J.
    Staley, B.
    Baghoomian, W.
    Katoh, N.
    Thomas, K. S.
    Apfelbacher, C. J.
    Simpson, E. L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (01) : 70 - 85
  • [24] The Self-Administered Eczema Area and Severity Index in Children with Moderate to Severe Atopic Dermatitis: Better Estimation of AD Body Surface Area Than Severity
    van Velsen, Sara G. A.
    Knol, Miriam J.
    Haeck, Inge M.
    Bruijnzeel-Koomen, Carla A. F. M.
    Pasmans, Suzanne G. M. A.
    PEDIATRIC DERMATOLOGY, 2010, 27 (05) : 470 - 475
  • [25] Product of Investigator Global Assessment and body surface area: a practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children
    Suh, T. P.
    Ramachandran, D.
    Patel, V.
    Jackson, K. L.
    Rangel, S. M.
    Fishbein, A. B.
    Paller, A. S.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E118 - E119
  • [26] Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme
    Barbier, N
    Paul, C
    Luger, T
    Allen, R
    De Prost, Y
    Papp, K
    Eichenfield, LF
    Cherill, R
    Hanifin, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (01) : 96 - 102
  • [27] Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
    Yosipovitch, Gil
    Bieber, Thomas
    Gold, Linda Stein
    Kwatra, Shawn
    Tatulych, Svitlana
    Nduaka, Chudy
    Cameron, Michael C.
    Williams, David
    Biswas, Pinaki
    Valdez, Hernan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB41 - AB41
  • [28] Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children
    Suh, Timothy P.
    Ramachandran, Divya
    Patel, Vidhi
    Jackson, Kathryn L.
    Rangel, Stephanie M.
    Fishbein, Anna B.
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (05) : 1187 - 1194
  • [29] Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6-11 years with severe atopic dermatitis (AD)
    Paller, Amy S.
    Cork, Michael J.
    Marcoux, Danielle
    Wollenberg, Andreas
    Prescilla, Randy
    Chen, Zhen
    Rossi, Ana B.
    Shumel, Brad
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB136 - AB136
  • [30] Dupilumab treatment provides improvements in signs of atopic dermatitis (AD) at week 100 in adult patients with moderate-to-severe AD who did not achieve ≥ 75% reduction in Eczema Area and Severity Index at week 16
    Armstrong, A.
    Blauvelt, A.
    Simpson, E. L.
    Chen, Z.
    Ardeleanu, M.
    Rossi, A. B.
    Tomondy, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E68 - E69